乳腺癌当代治疗后淋巴水肿风险:7617例多学科视角分析
多因素分析显示高BMI、淋巴结清扫数目多、含紫杉类方案、全乳切除、较大照射野和常规分割与淋巴水肿强相关(均P<0.001),据此构建的列线图内部一致性指数0.774,外部验证亚洲0.832、西方0.820。
要点
- 放疗野越大淋巴水肿风险越高,含腋窝I-II区照射时3年发生率达24.1%
- 大分割放疗较常规分割淋巴水肿发生率更低(6.8% vs 13.5%)
- 基于多因素构建的列线图可个体化预测淋巴水肿风险并获内外部验证
核心结论
- 乳腺癌三模式治疗因素交互促进淋巴水肿,多学科降阶梯策略可能降低淋巴水肿风险。
研究设计与样本
- 回顾性收集2007—2015年单中心5549例接受手术的乳腺癌患者治疗相关数据,并复核个体放疗计划的区域淋巴结照射野设计与分割方式。
- 构建淋巴水肿风险列线图,内部采用100次bootstrap样本验证,外部采用1877例亚洲和191例西方患者两个独立数据集验证。
主要发现
- 3年淋巴水肿发生率随照射体积增大而升高:无区域淋巴结照射 vs 区域淋巴结照射不含腋窝I-II区 vs 含腋窝I-II区为5.7% vs 16.8% vs 24.1%。
- 常规分割较大分割3年淋巴水肿发生率更高:13.5% vs 6.8%。
- 多因素分析中较高体重指数、较多清扫淋巴结数、含紫杉类方案、全乳切除、较大照射野和常规分割与淋巴水肿强相关(均P<0.001)。
- 列线图校准与区分度良好,内部一致性指数0.774,外部亚洲患者0.832、西方患者0.820。
关键数值与推荐
- 3年淋巴水肿发生率:无区域淋巴结照射5.7%、区域淋巴结照射不含腋窝I-II区16.8%、含腋窝I-II区24.1%。
- 3年淋巴水肿发生率:常规分割13.5% vs 大分割6.8%。
- 多因素分析中较高体重指数、较多清扫淋巴结数、含紫杉类方案、全乳切除、较大照射野和常规分割均P<0.001。
- 列线图一致性指数:内部0.774,外部亚洲0.832、西方0.820。
临床怎么用
- 可依据体重指数、清扫淋巴结数、化疗方案、手术方式、照射野和分割方式评估个体淋巴水肿风险。
- 在多学科决策中考虑降阶梯策略:减少淋巴结清扫、优化化疗方案、缩小放疗野和调整剂量分割以降低淋巴水肿风险。
局限性
- 为单中心回顾性研究,治疗相关数据来自回顾性收集。
- 外部验证数据集样本量分别为1877例亚洲患者和191例西方患者,西方样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to identify the comprehensive risk factors for lymphedema, thereby enabling a more informed multidisciplinary treatment decision-making. SUMMARY BACKGROUND DATA: Lymphedema is a serious long-term complication in breast cancer patients post-surgery; however, the influence of multimodal therapy on its occurrence remains unclear. METHODS: We retrospectively collected treatment-related data from 5549 breast cancer patients who underwent surgery between 2007 and 2015 at our institution. Individual radiotherapy plans were reviewed for regional nodal irradiation (RNI) field design and fractionation type. We identified lymphedema risk factors and used them to construct nomograms to predict individual risk of lymphedema. Nomograms were validated internally using 100 bootstrap samples and externally using 2 separate datasets of 1877 Asian and 191 Western patients. RESULTS: Six hundred thirty-nine patients developed lymphedema during a median follow-up of 60 months. The 3-year lymphedema incidence was 10.5%; this rate increased with larger irradiation volumes (no RNI vs RNI excluding axilla I-II vs RNI including axilla I-II: 5.7% vs 16.8% vs 24.1%) and when using conventional fractionation instead of hypofractionation (13.5% vs 6.8%). On multivariate analysis, higher body mass index, larger number of dissected nodes, taxane-based regimen, total mastectomy, larger irradiation field, and conventional fractionation were strongly associated with lymphedema (all P < 0.001). Nomograms constructed based on these variables showed good calibration and discrimination internally (concordance index: 0.774) and externally (0.832 for Asian and 0.820 for Western patients). CONCLUSIONS: Trimodality breast cancer treatment factors interact to promote lymphedema. Lymphedema risk can be decreased by deintensifying node dissection, chemotherapy regimen, and field and dose of radiotherapy. Deescalation strategies on a multidisciplinary basis might minimize lymphedema risk.
引用
- Byun HK, Chang JS, Im SH, et al. Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective. Ann Surg. 2021. PMID: 31348041. doi:10.1097/SLA.0000000000003491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。